Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open-label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of the TEAD Inhibitor TYK-01054 Capsules in Patients With Locally Advanced or Metastatic Advanced Solid Tumors

NCT07282873 is registered in ClinicalTrials.gov with TYK Medicines, Inc as lead sponsor.

NCT NCT07282873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07282873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open-label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of the TEAD Inhibitor TYK-01054 Capsules in Patients With Locally Advanced or Metastatic Advanced Solid Tumors
Lead sponsor
TYK Medicines, Inc
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
January 1, 2026
Completion date
June 30, 2029
Enrollment
219 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant mesothelioma (mm), solid tumor malignancies